Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 13/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.79 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.78 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.78 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22206583 | 0.98 | NT5E (1.00) | NT5EADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL22206598 | 0.97 | NT5E (1.00) | NT5EADORA3ADORA2AADORA1 | |
| SCHEMBL23633830 | 0.93 | NT5E (0.86) | NT5EADORA3ADORA2AADORA1 | |
| SCHEMBL22206596 | 0.93 | NT5E (0.86) | NT5EADORA3ADORA2AADORA1 | |
| SCHEMBL22215152 | 0.93 | NT5E (0.86) | NT5EADORA3ADORA2AADORA1 | |
| SCHEMBL22206637 | 0.92 | NT5E (0.85) | NT5EADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL21348740 | 0.92 | NT5E (0.87) | NT5EADORA3 | |
| SCHEMBL22206601 | 0.91 | NT5E (0.89) | NT5EADORA3ADORA2AADORA1 | |
| SCHEMBL22214993 | 0.91 | NT5E (0.89) | NT5EADORA3ADORA2AADORA1 | |
| SCHEMBL22215099 | 0.91 | NT5E (0.89) | NT5EADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319113-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ARCUS BIOSCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12433836-B2 | Parenterally administered immune enhancing drugs | ARCUS BIOSCIENCES, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-12168023-B2 | Inhibitors of adenosine 5′-nucleotidase | ARCUS BIOSCIENCES, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240285665-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ARCUS BIOSCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| US-11058704-B2 | Inhibitors of adenosine 5′-nucleotidase | ARCUS BIOSCIENCES, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11058704-B2 | Inhibitors of adenosine 5′-nucleotidase | ARCUS BIOSCIENCES, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | ARCUS BIOSCIENCES, INC. | 2020-12-31 | — | — | US | disclosed |
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | ARCUS BIOSCIENCES, INC. | 2020-12-31 | — | — | US | disclosed |
| US-20200222441-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ARCUS BIOSCIENCES, INC. | 2020-07-16 | — | — | US | disclosed |
| US-20200222441-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ARCUS BIOSCIENCES, INC. | 2020-07-16 | — | — | US | disclosed |
| WO-2019173682-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | ARCUS BIOSCIENCES, INC. (US) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | NT5C2, ADA, ENTPD1 | NT5E 10/4885ADORA3 19/4885ADORA2A 11/4885 |
| US-11058704-B2 | Inhibitors of adenosine 5′-nucleotidase | ENTPD5, NT5C2, ENTPD1 | NT5E 4/4885ADORA3 34/4885ADORA2A 19/4885 |
| US-20250319113-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ENTPD5, NT5C2, ENTPD1 | NT5E 4/4885ADORA3 34/4885ADORA2A 19/4885 |
| US-12168023-B2 | Inhibitors of adenosine 5′-nucleotidase | ENTPD5, NT5C2, ENTPD1 | NT5E 4/4885ADORA3 34/4885ADORA2A 19/4885 |
| US-12433836-B2 | Parenterally administered immune enhancing drugs | NT5C2, ADA, ENTPD1 | NT5E 10/4885ADORA3 19/4885ADORA2A 11/4885 |
| US-20200222441-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ENTPD5, NT5C2, ENTPD1 | NT5E 4/4885ADORA3 34/4885ADORA2A 19/4885 |
| US-20240285665-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ENTPD5, NT5C2, ENTPD1 | NT5E 4/4885ADORA3 34/4885ADORA2A 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.